Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants

ClinicalTrials.gov ID: NCT02325791

Public ClinicalTrials.gov record NCT02325791. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 1:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study was to evaluate the efficacy, safety, pharmacokinetics (PK), and immunogenicity of suptavumab (REGN2222) in infants born no more than 35 weeks, 6 days gestational age who are no more than 6 months of age at the time of enrollment in their respective geographic location. In order to optimize the potential benefit in this vulnerable population, we conducted this study during the RSV season using dosing regimens that are expected to be effective.

Study identification

NCT ID
NCT02325791
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Regeneron Pharmaceuticals
Industry
Enrollment
1,177 participants

Conditions and interventions

Eligibility (public fields only)

Age range
Up to 6 Months
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 20, 2015
Primary completion
Jul 4, 2017
Completion
Sep 25, 2017
Last update posted
Nov 5, 2018

2015 – 2017

United States locations

U.S. sites
107
U.S. states
36
U.S. cities
107
Facility City State ZIP Site status
Regeneron Investigational Site Birmingham Alabama
Regeneron Study Site Mobile Alabama
Regeneron Study Site Little Rock Arkansas
Regeneron Study Site Anaheim California
Regeneron Study Site Bell Gardens California
Regeneron Study Site Dinuba California
Regeneron Study Site Downey California
Regeneron Study Site Huntington Beach California
Regeneron Study Site La Puente California
Regeneron Study Site Los Angeles California
Regeneron Study Site Madera California
Regeneron Study Site Palmdale California
Regeneron Study Site Ventura California
Regeneron Study Site West Covina California
Regeneron Study Site Aurora Colorado
Regeneron Study Site Thornton Colorado
Regeneron Study Site Hartford Connecticut
Regeneron Study Site Boynton Beach Florida
Regeneron Study Site Gainesville Florida
Regeneron Study Site Jacksonville Florida
Regeneron Study Site Miami Florida
Regeneron Study Site Orlando Florida
Regeneron Study Site Pensacola Florida
Regeneron Study Site Tampa Florida
Regeneron Study Site Winter Park Florida
Regeneron Study Site Atlanta Georgia
Regeneron Study Site Columbus Georgia
Regeneron Study Site Dalton Georgia
Regeneron Study Site Meridian Idaho
Regeneron Study Site Nampa Idaho
Regeneron Study Site Peoria Illinois
Regeneron Study Site South Bend Indiana
Regeneron Study Site Hutchinson Kansas
Regeneron Study Site Topeka Kansas
Regeneron Study Site Bardstown Kentucky
Regeneron Study Site Louisville Kentucky
Regeneron Study Site Metairie Louisiana
Regeneron Study Site New Orleans Louisiana
Regeneron Study Site Shreveport Louisiana
Regeneron Study Site Baltimore Maryland
Regeneron Study Site Silver Spring Maryland
Regeneron Study Site Fall River Massachusetts
Regeneron Study Site Woburn Massachusetts
Regeneron Study Site Stevensville Michigan
Regeneron Study Site Duluth Minnesota
Regeneron Study Site Minneapolis Minnesota
Regeneron Study Site Saint Paul Minnesota
Regeneron Study Site Jackson Mississippi
Regeneron Study Site Bridgeton Missouri
Regeneron Study Site Kansas City Missouri
Regeneron Study Site Lincoln Nebraska
Regeneron Study Site Norfolk Nebraska
Regeneron Study Site Omaha Nebraska
Regeneron Study Site Reno Nevada
Regeneron Study Site Lebanon New Hampshire
Regeneron Study Site Neptune City New Jersey
Regeneron Study Site New Brunswick New Jersey
Regeneron Study Site Brooklyn New York
Regeneron Study Site Mineola New York
Regeneron Study Site New Hyde Park New York
Regeneron Study Site New York New York
Regeneron Study Site Rochester New York
Regeneron Study Site Syracuse New York
Regeneron Study Site The Bronx New York
Regeneron Study Site Boone North Carolina
Regeneron Study Site Chapel Hill North Carolina
Regeneron Study Site Durham North Carolina
Regeneron Study Site Raleigh North Carolina
Regeneron Study Site Cincinnati Ohio
Regeneron Study Site Cleveland Ohio
Regeneron Study Site Columbus Ohio
Regeneron Study Site Dayton Ohio
Regeneron Study Site Fairfield Ohio
Regeneron Study Site Mayfield Heights Ohio
Regeneron Study Site Toledo Ohio
Regeneron Study Site Youngstown Ohio
Regeneron Study Site Oklahoma City Oklahoma
Regeneron Study Site Tulsa Oklahoma
Regeneron Study Site Gresham Oregon
Regeneron Study Site Allentown Pennsylvania
Regeneron Study Site Erie Pennsylvania
Regeneron Study Site Hermitage Pennsylvania
Regeneron Study Site Charleston South Carolina
Regeneron Study Site Cheraw South Carolina
Regeneron Study Site Greenville South Carolina
Regeneron Study Site North Charleston South Carolina
Regeneron Study Site Alcoa Tennessee
Regeneron Study Site Kingsport Tennessee
Regeneron Study Site Nashville Tennessee
Regeneron Study Site Austin Texas
Regeneron Study Site Fort Sam Houston Texas
Regeneron Study Site Houston Texas
Regeneron Study Site San Antonio Texas
Regeneron Study Site Layton Utah
Regeneron Study Site Roy Utah
Regeneron Study Site St. George Utah
Regeneron Study Site Syracuse Utah
Regeneron Study Site Charlottesville Virginia
Regeneron Study Site Midlothian Virginia
Regeneron Study Site Richmond Virginia
Regeneron Study Site Vienna Virginia
Regeneron Study Site Huntington West Virginia
Regeneron Study Site Kingwood West Virginia
Regeneron Study Site Morgantown West Virginia
Regeneron Study Site Madison Wisconsin
Regeneron Study Site Marshfield Wisconsin
Regeneron Study Site Milwaukee Wisconsin

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 98 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02325791, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 5, 2018 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02325791 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →